BioSpace News Archive

RELIEF THERAPEUTICS Holding SA announced its new state-of-the-art laboratory has been audited and approved by the Swiss Agency for Therapeutic Products and meets Good Manufacturing Practice standards.

OMass Therapeutics announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new investor British Patient Capital in a Series B extension, bringing the total raised in this round to £85.5 million.

Beckman Coulter, a clinical diagnostics leader, unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint.

150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction or intensive reinduction in the 2nd, 3rd, or 4th salvage of AML and the 1st interim analysis of this study shall be done for NDA approval to the FDA in US soon after confirmation of the superiority of DFP-10917 arm.

Biophytis SA announced that it has submitted the application for Clinical Trial Authorization to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA.

RaySearch Laboratories AB is pleased to announce that the strategic partnership with BEBIG Medical, which began in 2018, has been extended through a memorandum of the agreement.

BioNxt Solutions Inc. is pleased to report that it has received government approval for to proceed with its comparative drug absorption study for the Company’s transdermal Rotigotine patch for the treatment of Parkinson’s disease.

NUCLIDIUM and PharmaLogic Holdings announced that they have entered into a strategic collaboration agreement for the production and clinical supply of 61Cu in the United States to accelerate the development of NUCLIDIUM’s theranostic pipeline.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the release of its second annual Equality Report covering 2022.

Visgenx, Inc. announced that the Company will be presenting results from pre-clinical studies of its gene therapy candidate for dry AMD at the American Society of Gene and Cell Therapy 2023 Annual Meeting being held May 16-20 at the Los Angeles Convention Center.